Lead Product(s): Landiolol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LDLL600
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Eagle Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Licensing Agreement August 09, 2021
The Company will support the submission of a new drug application to the U.S. FDA seeking approval for Landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.